Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region

Market Scenario

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026. Nanomedicine Market Drivers and Restrains: Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth. The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Nanomedicine Market Segmentation Analysis: Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration. Nanomedicine Market Regional Analysis: Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future. Nanomedicine Market Competitive landscape Major Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investor’s guide.

Scope of the Nanomedicine Market:

Nanomedicine Market  by Modality:

• Diagnostics • Treatments

Nanomedicine Market  by Diseases:

• Oncological Diseases • Infectious Diseases • Cardiovascular Diseases • Orthopedic Disorders • Neurological Diseases • Urological Diseases • Ophthalmological Diseases • Immunological Diseases

Nanomedicine Market  by Application:

• Neurology • Cardiovascular • Anti-Inflammatory • Anti-Infectives • Oncology

Nanomedicine Market by Region:

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Nanomedicine Market  Major Players:

• Abbott Laboratories • CombiMatrix Corporation • General Electric Company • Sigma-Tau Pharmaceuticals, Inc • Johnson & Johnson • Mallinckrodt plc. • Merck & Company, Inc. • Nanosphere, Inc. • Pfizer, Inc. • Teva Pharmaceutical Industries Ltd. • Celgene Corporation • UCB (Union Chimique Belge) S.A. • AMAG Pharmaceuticals • Nanospectra Biosciences, Inc. • Arrowhead Pharmaceuticals, Inc. • Leadiant Biosciences, Inc. • Epeius Biotechnologies Corporation • Cytimmune Sciences, Inc. Global Dental Chair Market

Table of Contents

Nanomedicine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Nanomedicine Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Nanomedicine Market Analysis and Forecast 6.1. Global Nanomedicine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Nanomedicine Market Analysis and Forecast, by Modality 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Nanomedicine Market Value Share Analysis, by Modality 7.4. Global Nanomedicine Market Size (US$ Mn) Forecast, by Modality 7.5. Global Nanomedicine Market Analysis, by Modality 7.6. Global Nanomedicine Market Attractiveness Analysis, by Modality 8. Global Nanomedicine Market Analysis and Forecast, by Diseases 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Nanomedicine Market Value Share Analysis, by Diseases 8.4. Global Nanomedicine Market Size (US$ Mn) Forecast, by Diseases 8.5. Global Nanomedicine Market Analysis, by Diseases 8.6. Global Nanomedicine Market Attractiveness Analysis, by Diseases 9. Global Nanomedicine Market Analysis and Forecast, by Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Nanomedicine Market Value Share Analysis, by Application 9.4. Global Nanomedicine Market Size (US$ Mn) Forecast, by Application 9.5. Global Nanomedicine Market Analysis, by Application 9.6. Global Nanomedicine Market Attractiveness Analysis, by Application 10. Global Nanomedicine Market Analysis, by Region 10.1. Global Nanomedicine Market Value Share Analysis, by Region 10.2. Global Nanomedicine Market Size (US$ Mn) Forecast, by Region 10.3. Global Nanomedicine Market Attractiveness Analysis, by Region 11. North America Nanomedicine Market Analysis 11.1. Key Findings 11.2. North America Nanomedicine Market Overview 11.3. North America Nanomedicine Market Value Share Analysis, by Modality 11.4. North America Nanomedicine Market Forecast, by Modality 11.4.1. Modality 11.4.1.1. Custodian Solution 11.4.1.2. Wallet Management 11.5. North America Nanomedicine Market Value Share Analysis, by Diseases 11.6. North America Nanomedicine Market Forecast, by Diseases 11.6.1. Oncological Diseases 11.6.2. Infectious Diseases 11.6.3. Cardiovascular Diseases 11.6.4. Orthopedic Disorders 11.6.5. Neurological Diseases 11.6.6. Urological Diseases 11.6.7. Ophthalmological Diseases 11.6.8. Immunological Diseases 11.7. North America Nanomedicine Market Value Share Analysis, by Application 11.8. North America Nanomedicine Market Forecast, by Application 11.8.1. Neurology 11.8.2. Cardiovascular 11.8.3. Anti-Inflammatory 11.8.4. Anti-Infectives 11.8.5. Oncology 11.9. North America Nanomedicine Market Value Share Analysis, by Country 11.10. North America Nanomedicine Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Nanomedicine Market Analysis, by Country 11.12. U.S. Nanomedicine Market Forecast, by Modality 11.12.1. Diagnostics 11.12.2. Treatments 11.13. U.S. Nanomedicine Market Forecast, by Diseases 11.13.1. Oncological Diseases 11.13.2. Infectious Diseases 11.13.3. Cardiovascular Diseases 11.13.4. Orthopedic Disorders 11.13.5. Neurological Diseases 11.13.6. Urological Diseases 11.13.7. Ophthalmological Diseases 11.13.8. Immunological Diseases 11.14. U.S. Nanomedicine Market Forecast, by Application 11.14.1. Neurology 11.14.2. Cardiovascular 11.14.3. Anti-Inflammatory 11.14.4. Anti-Infectives 11.14.5. Oncology 11.15. Canada Nanomedicine Market Forecast, by Modality 11.15.1. Diagnostics 11.15.2. Treatments 11.16. Steel Canada Nanomedicine Market Forecast, by Diseases 11.16.1. Oncological Diseases 11.16.2. Infectious Diseases 11.16.3. Cardiovascular Diseases 11.16.4. Orthopedic Disorders 11.16.5. Neurological Diseases 11.16.6. Urological Diseases 11.16.7. Ophthalmological Diseases 11.16.8. Immunological Diseases 11.17. Canada Nanomedicine Market Forecast, by Application 11.17.1. Neurology 11.17.2. Cardiovascular 11.17.3. Anti-Inflammatory 11.17.4. Anti-Infectives 11.17.5. Oncology 11.18. North America Nanomedicine Market Attractiveness Analysis 11.18.1. By Modality 11.18.2. By Diseases 11.18.3. By Application 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Nanomedicine Market Analysis 12.1. Key Findings 12.2. Europe Nanomedicine Market Overview 12.3. Europe Nanomedicine Market Value Share Analysis, by Modality 12.4. Europe Nanomedicine Market Forecast, by Modality 12.4.1. Diagnostics 12.4.2. Treatments 12.5. Europe Nanomedicine Market Value Share Analysis, by Diseases 12.6. Europe Nanomedicine Market Forecast, by Diseases 12.6.1. Oncological Diseases 12.6.2. Infectious Diseases 12.6.3. Cardiovascular Diseases 12.6.4. Orthopedic Disorders 12.6.5. Neurological Diseases 12.6.6. Urological Diseases 12.6.7. Ophthalmological Diseases 12.6.8. Immunological Diseases 12.7. Europe Nanomedicine Market Value Share Analysis, by Application 12.8. Europe Nanomedicine Market Forecast, by Application 12.8.1. Neurology 12.8.2. Cardiovascular 12.8.3. Anti-Inflammatory 12.8.4. Anti-Infectives 12.8.5. Oncology 12.9. Europe Nanomedicine Market Value Share Analysis, by Country 12.10. Europe Nanomedicine Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Nanomedicine Market Analysis, by Country 12.12. Germany Nanomedicine Market Forecast, by Modality 12.12.1. Diagnostics 12.12.2. Treatments 12.13. Germany Nanomedicine Market Forecast, by Diseases 12.13.1. Oncological Diseases 12.13.2. Infectious Diseases 12.13.3. Cardiovascular Diseases 12.13.4. Orthopedic Disorders 12.13.5. Neurological Diseases 12.13.6. Urological Diseases 12.13.7. Ophthalmological Diseases 12.13.8. Immunological Diseases 12.14. Germany Nanomedicine Market Forecast, by Application 12.14.1. Neurology 12.14.2. Cardiovascular 12.14.3. Anti-Inflammatory 12.14.4. Anti-Infectives 12.14.5. Oncology 12.15. U.K. Nanomedicine Market Forecast, by Modality 12.15.1. Diagnostics 12.15.2. Treatments 12.16. U.K. Nanomedicine Market Forecast, by Diseases 12.16.1. Oncological Diseases 12.16.2. Infectious Diseases 12.16.3. Cardiovascular Diseases 12.16.4. Orthopedic Disorders 12.16.5. Neurological Diseases 12.16.6. Urological Diseases 12.16.7. Ophthalmological Diseases 12.16.8. Immunological Diseases 12.17. U.K. Nanomedicine Market Forecast, by Application 12.17.1. Neurology 12.17.2. Cardiovascular 12.17.3. Anti-Inflammatory 12.17.4. Anti-Infectives 12.17.5. Oncology 12.18. France Nanomedicine Market Forecast, by Modality 12.18.1. Diagnostics 12.18.2. Treatments 12.19. France Nanomedicine Market Forecast, by Diseases 12.19.1. Oncological Diseases 12.19.2. Infectious Diseases 12.19.3. Cardiovascular Diseases 12.19.4. Orthopedic Disorders 12.19.5. Neurological Diseases 12.19.6. Urological Diseases 12.19.7. Ophthalmological Diseases 12.19.8. Immunological Diseases 12.20. France Nanomedicine Market Forecast, by Application 12.20.1. Neurology 12.20.2. Cardiovascular 12.20.3. Anti-Inflammatory 12.20.4. Anti-Infectives 12.20.5. Oncology 12.21. Italy Nanomedicine Market Forecast, by Modality 12.21.1. Diagnostics 12.21.2. Treatments 12.22. Italy Nanomedicine Market Forecast, by Diseases 12.22.1. Oncological Diseases 12.22.2. Infectious Diseases 12.22.3. Cardiovascular Diseases 12.22.4. Orthopedic Disorders 12.22.5. Neurological Diseases 12.22.6. Urological Diseases 12.22.7. Ophthalmological Diseases 12.22.8. Immunological Diseases 12.23. Italy Nanomedicine Market Forecast, by Application 12.23.1. Neurology 12.23.2. Cardiovascular 12.23.3. Anti-Inflammatory 12.23.4. Anti-Infectives 12.23.5. Oncology 12.24. Spain Nanomedicine Market Forecast, by Modality 12.24.1. Diagnostics 12.24.2. Treatments 12.25. Spain Nanomedicine Market Forecast, by Diseases 12.25.1. Oncological Diseases 12.25.2. Infectious Diseases 12.25.3. Cardiovascular Diseases 12.25.4. Orthopedic Disorders 12.25.5. Neurological Diseases 12.25.6. Urological Diseases 12.25.7. Ophthalmological Diseases 12.25.8. Immunological Diseases 12.26. Spain Nanomedicine Market Forecast, by Application 12.26.1. Neurology 12.26.2. Cardiovascular 12.26.3. Anti-Inflammatory 12.26.4. Anti-Infectives 12.26.5. Oncology 12.27. Rest of Europe Nanomedicine Market Forecast, by Modality 12.27.1. Diagnostics 12.27.2. Treatments 12.28. Rest of Europe Nanomedicine Market Forecast, by Diseases 12.28.1. Oncological Diseases 12.28.2. Infectious Diseases 12.28.3. Cardiovascular Diseases 12.28.4. Orthopedic Disorders 12.28.5. Neurological Diseases 12.28.6. Urological Diseases 12.28.7. Ophthalmological Diseases 12.28.8. Immunological Diseases 12.29. Rest Of Europe Nanomedicine Market Forecast, by Application 12.29.1. Neurology 12.29.2. Cardiovascular 12.29.3. Anti-Inflammatory 12.29.4. Anti-Infectives 12.29.5. Oncology 12.30. Europe Nanomedicine Market Attractiveness Analysis 12.30.1. By Modality 12.30.2. By Diseases 12.30.3. By Application 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Nanomedicine Market Analysis 13.1. Key Findings 13.2. Asia Pacific Nanomedicine Market Overview 13.3. Asia Pacific Nanomedicine Market Value Share Analysis, by Modality 13.4. Asia Pacific Nanomedicine Market Forecast, by Modality 13.4.1. Diagnostics 13.4.2. Treatments 13.5. Asia Pacific Nanomedicine Market Value Share Analysis, by Diseases 13.6. Asia Pacific Nanomedicine Market Forecast, by Diseases 13.6.1. Oncological Diseases 13.6.2. Infectious Diseases 13.6.3. Cardiovascular Diseases 13.6.4. Orthopedic Disorders 13.6.5. Neurological Diseases 13.6.6. Urological Diseases 13.6.7. Ophthalmological Diseases 13.6.8. Immunological Diseases 13.7. Asia Pacific Nanomedicine Market Value Share Analysis, by Application 13.8. Asia Pacific Nanomedicine Market Forecast, by Application 13.8.1. Neurology 13.8.2. Cardiovascular 13.8.3. Anti-Inflammatory 13.8.4. Anti-Infectives 13.8.5. Oncology 13.9. Asia Pacific Nanomedicine Market Value Share Analysis, by Country 13.10. Asia Pacific Nanomedicine Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Nanomedicine Market Analysis, by Country 13.12. China Nanomedicine Market Forecast, by Modality 13.12.1. Diagnostics 13.12.2. Treatments 13.13. China Nanomedicine Market Forecast, by Diseases 13.13.1. Oncological Diseases 13.13.2. Infectious Diseases 13.13.3. Cardiovascular Diseases 13.13.4. Orthopedic Disorders 13.13.5. Neurological Diseases 13.13.6. Urological Diseases 13.13.7. Ophthalmological Diseases 13.13.8. Immunological Diseases 13.14. China Nanomedicine Market Forecast, by Application 13.14.1. Neurology 13.14.2. Cardiovascular 13.14.3. Anti-Inflammatory 13.14.4. Anti-Infectives 13.14.5. Oncology 13.15. India Nanomedicine Market Forecast, by Modality 13.15.1. Diagnostics 13.15.2. Treatments 13.16. India Nanomedicine Market Forecast, by Diseases 13.16.1. Oncological Diseases 13.16.2. Infectious Diseases 13.16.3. Cardiovascular Diseases 13.16.4. Orthopedic Disorders 13.16.5. Neurological Diseases 13.16.6. Urological Diseases 13.16.7. Ophthalmological Diseases 13.16.8. Immunological Diseases 13.17. India Nanomedicine Market Forecast, by Application 13.17.1. Neurology 13.17.2. Cardiovascular 13.17.3. Anti-Inflammatory 13.17.4. Anti-Infectives 13.17.5. Oncology 13.18. Japan Nanomedicine Market Forecast, by Modality 13.18.1. Diagnostics 13.18.2. Treatments 13.19. Japan Nanomedicine Market Forecast, by Diseases 13.19.1. Oncological Diseases 13.19.2. Infectious Diseases 13.19.3. Cardiovascular Diseases 13.19.4. Orthopedic Disorders 13.19.5. Neurological Diseases 13.19.6. Urological Diseases 13.19.7. Ophthalmological Diseases 13.19.8. Immunological Diseases 13.20. Japan Nanomedicine Market Forecast, by Application 13.20.1. Neurology 13.20.2. Cardiovascular 13.20.3. Anti-Inflammatory 13.20.4. Anti-Infectives 13.20.5. Oncology 13.21. ASEAN Nanomedicine Market Forecast, by Modality 13.21.1. Diagnostics 13.21.2. Treatments 13.22. ASEAN Nanomedicine Market Forecast, by Diseases 13.22.1. Oncological Diseases 13.22.2. Infectious Diseases 13.22.3. Cardiovascular Diseases 13.22.4. Orthopedic Disorders 13.22.5. Neurological Diseases 13.22.6. Urological Diseases 13.22.7. Ophthalmological Diseases 13.22.8. Immunological Diseases 13.23. ASEAN Nanomedicine Market Forecast, by Application 13.23.1. Neurology 13.23.2. Cardiovascular 13.23.3. Anti-Inflammatory 13.23.4. Anti-Infectives 13.23.5. Oncology 13.24. Rest of Asia Pacific Nanomedicine Market Forecast, by Modality 13.24.1. Diagnostics 13.24.2. Treatments 13.25. Rest of Asia Pacific Nanomedicine Market Forecast, by Diseases 13.25.1. Oncological Diseases 13.25.2. Infectious Diseases 13.25.3. Cardiovascular Diseases 13.25.4. Orthopedic Disorders 13.25.5. Neurological Diseases 13.25.6. Urological Diseases 13.25.7. Ophthalmological Diseases 13.25.8. Immunological Diseases 13.26. Rest of Asia Pacific Nanomedicine Market Forecast, by Application 13.26.1. Neurology 13.26.2. Cardiovascular 13.26.3. Anti-Inflammatory 13.26.4. Anti-Infectives 13.26.5. Oncology 13.27. Asia Pacific Nanomedicine Market Attractiveness Analysis 13.27.1. By Modality 13.27.2. By Diseases 13.27.3. By Application 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Nanomedicine Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Nanomedicine Market Overview 14.3. Middle East & Africa Nanomedicine Market Value Share Analysis, by Modality 14.4. Middle East & Africa Nanomedicine Market Forecast, by Modality 14.4.1. Diagnostics 14.4.2. Treatments 14.5. Middle East & Africa Nanomedicine Market Value Share Analysis, by Diseases 14.6. Middle East & Africa Nanomedicine Market Forecast, by Diseases 14.6.1. Oncological Diseases 14.6.2. Infectious Diseases 14.6.3. Cardiovascular Diseases 14.6.4. Orthopedic Disorders 14.6.5. Neurological Diseases 14.6.6. Urological Diseases 14.6.7. Ophthalmological Diseases 14.6.8. Immunological Diseases 14.7. Middle East & Africa Nanomedicine Market Value Share Analysis, by Application 14.8. Middle East & Africa Nanomedicine Market Forecast, by Application 14.8.1. Neurology 14.8.2. Cardiovascular 14.8.3. Anti-Inflammatory 14.8.4. Anti-Infectives 14.8.5. Oncology 14.9. Middle East & Africa Nanomedicine Market Value Share Analysis, by Country 14.10. Middle East & Africa Nanomedicine Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Nanomedicine Market Analysis, by Country 14.12. GCC Nanomedicine Market Forecast, by Modality 14.12.1. Diagnostics 14.12.2. Treatments 14.13. GCC Nanomedicine Market Forecast, by Diseases 14.13.1. Oncological Diseases 14.13.2. Infectious Diseases 14.13.3. Cardiovascular Diseases 14.13.4. Orthopedic Disorders 14.13.5. Neurological Diseases 14.13.6. Urological Diseases 14.13.7. Ophthalmological Diseases 14.13.8. Immunological Diseases 14.14. GCC Nanomedicine Market Forecast, by Application 14.14.1. Neurology 14.14.2. Cardiovascular 14.14.3. Anti-Inflammatory 14.14.4. Anti-Infectives 14.14.5. Oncology 14.15. South Africa Nanomedicine Market Forecast, by Modality 14.15.1. Diagnostics 14.15.2. Treatments 14.16. South Africa Nanomedicine Market Forecast, by Diseases 14.16.1. Oncological Diseases 14.16.2. Infectious Diseases 14.16.3. Cardiovascular Diseases 14.16.4. Orthopedic Disorders 14.16.5. Neurological Diseases 14.16.6. Urological Diseases 14.16.7. Ophthalmological Diseases 14.16.8. Immunological Diseases 14.17. South Africa Nanomedicine Market Forecast, by Application 14.17.1. Neurology 14.17.2. Cardiovascular 14.17.3. Anti-Inflammatory 14.17.4. Anti-Infectives 14.17.5. Oncology 14.18. Rest of Middle East & Africa Nanomedicine Market Forecast, by Modality 14.18.1. Diagnostics 14.18.2. Treatments 14.19. Rest of Middle East & Africa Nanomedicine Market Forecast, by Diseases 14.19.1. Oncological Diseases 14.19.2. Infectious Diseases 14.19.3. Cardiovascular Diseases 14.19.4. Orthopedic Disorders 14.19.5. Neurological Diseases 14.19.6. Urological Diseases 14.19.7. Ophthalmological Diseases 14.19.8. Immunological Diseases 14.20. Rest of Middle East & Africa Nanomedicine Market Forecast, by Application 14.20.1. Neurology 14.20.2. Cardiovascular 14.20.3. Anti-Inflammatory 14.20.4. Anti-Infectives 14.20.5. Oncology 14.21. Middle East & Africa Nanomedicine Market Attractiveness Analysis 14.21.1. By Modality 14.21.2. By Diseases 14.21.3. By Application 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Nanomedicine Market Analysis 15.1. Key Findings 15.2. South America Nanomedicine Market Overview 15.3. South America Nanomedicine Market Value Share Analysis, by Modality 15.4. South America Nanomedicine Market Forecast, by Modality 15.4.1. Diagnostics 15.4.2. Treatments 15.5. South America Nanomedicine Market Value Share Analysis, by Diseases 15.6. South America Nanomedicine Market Forecast, by Diseases 15.6.1. Oncological Diseases 15.6.2. Infectious Diseases 15.6.3. Cardiovascular Diseases 15.6.4. Orthopedic Disorders 15.6.5. Neurological Diseases 15.6.6. Urological Diseases 15.6.7. Ophthalmological Diseases 15.6.8. Immunological Diseases 15.7. South America Nanomedicine Market Value Share Analysis, by Application 15.8. South America Nanomedicine Market Forecast, by Application 15.8.1. Neurology 15.8.2. Cardiovascular 15.8.3. Anti-Inflammatory 15.8.4. Anti-Infectives 15.8.5. Oncology 15.9. South America Nanomedicine Market Value Share Analysis, by Country 15.10. South America Nanomedicine Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Nanomedicine Market Analysis, by Country 15.12. Brazil Nanomedicine Market Forecast, by Modality 15.12.1. Diagnostics 15.12.2. Treatments 15.13. Brazil Nanomedicine Market Forecast, by Diseases 15.13.1. Oncological Diseases 15.13.2. Infectious Diseases 15.13.3. Cardiovascular Diseases 15.13.4. Orthopedic Disorders 15.13.5. Neurological Diseases 15.13.6. Urological Diseases 15.13.7. Ophthalmological Diseases 15.13.8. Immunological Diseases 15.14. Brazil Nanomedicine Market Forecast, by Application 15.14.1. Neurology 15.14.2. Cardiovascular 15.14.3. Anti-Inflammatory 15.14.4. Anti-Infectives 15.14.5. Oncology 15.15. Mexico Nanomedicine Market Forecast, by Modality 15.15.1. Diagnostics 15.15.2. Treatments 15.16. Mexico Nanomedicine Market Forecast, by Diseases 15.16.1. Oncological Diseases 15.16.2. Infectious Diseases 15.16.3. Cardiovascular Diseases 15.16.4. Orthopedic Disorders 15.16.5. Neurological Diseases 15.16.6. Urological Diseases 15.16.7. Ophthalmological Diseases 15.16.8. Immunological Diseases 15.17. Mexico Nanomedicine Market Forecast, by Application 15.17.1. Neurology 15.17.2. Cardiovascular 15.17.3. Anti-Inflammatory 15.17.4. Anti-Infectives 15.17.5. Oncology 15.18. Rest of South America Nanomedicine Market Forecast, by Modality 15.18.1. Diagnostics 15.18.2. Treatments 15.19. Rest of South America Nanomedicine Market Forecast, by Diseases 15.19.1. Oncological Diseases 15.19.2. Infectious Diseases 15.19.3. Cardiovascular Diseases 15.19.4. Orthopedic Disorders 15.19.5. Neurological Diseases 15.19.6. Urological Diseases 15.19.7. Ophthalmological Diseases 15.19.8. Immunological Diseases 15.20. Rest of South America Nanomedicine Market Forecast, by Application 15.20.1. Neurology 15.20.2. Cardiovascular 15.20.3. Anti-Inflammatory 15.20.4. Anti-Infectives 15.20.5. Oncology 15.21. South America Nanomedicine Market Attractiveness Analysis 15.21.1. By Modality 15.21.2. By Diseases 15.21.3. By Application 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Abbott Laboratories 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. CombiMatrix Corporation 16.3.3. General Electric Company 16.3.4. Sigma-Tau Pharmaceuticals, Inc 16.3.5. Johnson & Johnson 16.3.6. Mallinckrodt plc. 16.3.7. Merck & Company, Inc. 16.3.8. Nanosphere, Inc. 16.3.9. Pfizer, Inc. 16.3.10. Teva Pharmaceutical Industries Ltd. 16.3.11. Celgene Corporation 16.3.12. UCB (Union Chimique Belge) S.A. 16.3.13. AMAG Pharmaceuticals 16.3.14. Nanospectra Biosciences, Inc. 16.3.15. Arrowhead Pharmaceuticals, Inc. 16.3.16. Leadiant Biosciences, Inc. 16.3.17. Epeius Biotechnologies Corporation 16.3.18. Cytimmune Sciences, Inc. 17. Primary Key Insights

About This Report

Report ID39223
Category Healthcare
Published DateDec 2019
No of Pages189
Contact Us
Call Now